Low-dose metronomic chemotherapy as an efficient treatment option in metastatic breast cancer—results of an exploratory case–control study
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Low-dose metronomic chemotherapy as an efficient treatment option in metastatic breast cancer—results of an exploratory case–control study
Authors
Keywords
-
Journal
BREAST CANCER RESEARCH AND TREATMENT
Volume 182, Issue 2, Pages 389-399
Publisher
Springer Science and Business Media LLC
Online
2020-06-04
DOI
10.1007/s10549-020-05711-5
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Metronomic chemotherapy of cyclophosphamide plus methotrexate for advanced breast cancer: Real‐world data analyses and experience of one center
- (2020) Qianyi Lu et al. Cancer Communications
- Metronomic Chemotherapy: A Systematic Review of the Literature and Clinical Experience
- (2019) Cem Simsek et al. Journal of Oncology
- The Role of CDK4/6 Inhibitors in Breast Cancer
- (2019) Conleth G. Murphy CURRENT TREATMENT OPTIONS IN ONCOLOGY
- Treating advanced breast cancer with metronomic chemotherapy: what is known, what is new and what is the future?
- (2019) Marina Elena Cazzaniga et al. OncoTargets and Therapy
- AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2019
- (2019) Marc Thill et al. Breast Care
- Suppressive impact of metronomic chemotherapy using UFT and/or cyclophosphamide on mediators of breast cancer dissemination and invasion
- (2019) Raquel Muñoz et al. PLoS One
- Metronomic chemotherapy for advanced breast cancer patients in the real world practice: Final results of the VICTOR-6 study
- (2019) M.E. Cazzaniga et al. BREAST
- 4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)†
- (2018) F Cardoso et al. ANNALS OF ONCOLOGY
- AGO Recommendations for the Diagnosis and Treatment of Patients with Advanced and Metastatic Breast Cancer: Update 2018
- (2018) Marc Thill et al. Breast Care
- Explorative Analysis of Low-Dose Metronomic Chemotherapy with Cyclophosphamide and Methotrexate in a Cohort of Metastatic Breast Cancer Patients
- (2018) Slavomir Krajnak et al. Breast Care
- Pan-European Expert Meeting on the Use of Metronomic Chemotherapy in Advanced Breast Cancer Patients: The PENELOPE Project
- (2018) Marina E. Cazzaniga et al. ADVANCES IN THERAPY
- Metronomic capecitabine combined with aromatase inhibitors for new chemoendocrine treatment of advanced breast cancer: a phase II clinical trial
- (2018) Jian-wei Li et al. BREAST CANCER RESEARCH AND TREATMENT
- A Combination of Immune Checkpoint Inhibition with Metronomic Chemotherapy as a Way of Targeting Therapy-Resistant Cancer Cells
- (2017) Irina Kareva INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Breast cancer
- (2017) Nadia Harbeck et al. LANCET
- Inhibition of tumor growth by cancer vaccine combined with metronomic chemotherapy and anti-PD-1 in a pre-clinical setting
- (2017) Annacarmen Petrizzo et al. Oncotarget
- The efficacy and toxicity profile of metronomic chemotherapy for metastatic breast cancer: A meta-analysis
- (2017) Yangyang Liu et al. PLoS One
- SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase III trial
- (2016) Christoph Rochlitz et al. BMC CANCER
- Metronomic chemotherapy with oral vinorelbine (mVNR) and capecitabine (mCAPE) in advanced HER2-negative breast cancer patients: is it a way to optimize disease control? Final results of the VICTOR-2 study
- (2016) M. E. Cazzaniga et al. BREAST CANCER RESEARCH AND TREATMENT
- Current achievements and future perspectives of metronomic chemotherapy
- (2016) Adriana Romiti et al. INVESTIGATIONAL NEW DRUGS
- Dose-Dense Chemotherapy in Metastatic Breast Cancer: Shortening the Time Interval for a Better Therapeutic Index
- (2015) Marcus Schmidt Breast Care
- Metastatic breast cancer patients treated with low-dose metronomic chemotherapy with cyclophosphamide and celecoxib: clinical outcomes and biomarkers of response
- (2015) Herman Andres Perroud et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Metronomic chemotherapy: An attractive alternative to maximum tolerated dose therapy that can activate anti-tumor immunity and minimize therapeutic resistance
- (2015) Irina Kareva et al. CANCER LETTERS
- New insights into metronomic chemotherapy-induced immunoregulation
- (2014) Yi-Bin Hao et al. CANCER LETTERS
- Low-dose metronomic chemotherapy: A systematic literature analysis
- (2013) K. Lien et al. EUROPEAN JOURNAL OF CANCER
- Oral delivery of anticancer drugs: Challenges and opportunities
- (2013) Kaushik Thanki et al. JOURNAL OF CONTROLLED RELEASE
- Combination antiangiogenic therapy in advanced breast cancer: a phase 1 trial of vandetanib, a VEGFR inhibitor, and metronomic chemotherapy, with correlative platelet proteomics
- (2012) Erica L. Mayer et al. BREAST CANCER RESEARCH AND TREATMENT
- Oral Metronomic Cyclophosphamide and Methotrexate Plus Fulvestrant in Advanced Breast Cancer Patients: A Mono-Institutional Case-Cohort Report
- (2012) Gaetano Aurilio et al. Breast Journal
- Metronomic oral combination chemotherapy with capecitabine and cyclophosphamide: a phase II study in patients with HER2-negative metastatic breast cancer
- (2012) Masataka Yoshimoto et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Low-Dose Metronomic Oral Administration of Vinorelbine in the First-line Treatment of Elderly Patients With Metastatic Breast Cancer
- (2010) Raffaele Addeo et al. Clinical Breast Cancer
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started